Abstract:Kirsten rats sarcoma viral oncogene (KRAS), the first discovered human oncogene, has long been recognized as "undruggable". KRAS mutations frequently occur in multiple human cancers including non-small cell lung cancer(NSCLC), colorectal cancer(CRC) and pancreatic ductal adenocarcinoma(PDAC), functioning as a "molecule switch" determining the activation of various oncogenic signaling pathways. Except for its intrinsic pro-tumorigenic role, KRAS alteration also exhibits an unique immune signature characterized by elevated PD-L1 level and high tumor mutational burden(TMB). KRAS mutation shape an immune suppressive microenvironment by impeding effective T cells infiltration and recruiting suppressive immune cells including myeloid-derived suppressor cells(MDSCs), regulatory T cells(Tregs), cancer associated fibroblasts(CAFs). In immune checkpoint inhibitor(ICI) era, NSCLC patients with mutated KRAS tend to be more responsive to ICI than patients with intact KRAS. The hallmark for KRAS mutation is the existence of multiple kinds of co-mutations. Different types of co-alterations have distinct tumor microenvironment(TME) signatures and responses to ICI. TP53 co-mutation possess a "hot" TME and achieve higher response to immunotherapy while other loss of function mutation correlated with a "colder" TME and a poor outcome to ICI-based therapy. The groundbreaking discovery of KRAS G12C inhibitors significantly improved outcomes for this KRAS subtype even though efficacy was limited to NSCLC patients. KRAS G12C inhibitors also restore the suppressive TME, creating an opportunity for combinations with ICI. However, an inevitable challenge to KRAS inhibitors is drug resistance. Promising combination strategies such as combination with SHP2 is an approach deserve further exploration because of their immune modulatory effect.

Kras Mutation in Tumorigenesis and Cancer Therapy

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

KRAS: A Promising Therapeutic Target for Cancer Treatment

The Function of RAS Mutation in Cancer and Advances in Its Drug Research

KRAS - an Evolving Cancer Target.

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Targeting Mutant KRAS for Anticancer Therapy

KRAS mutation: from undruggable to druggable in cancer

Post-translational modification of KRAS: potential targets for cancer therapy

Targeting KRAS in cancer

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

Emerging strategies to target RAS signaling in human cancer therapy

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies

Rationale for RAS mutation-tailored therapies

Unveiling the role of KRAS in tumor immune microenvironment

Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer